Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Alexandria Real Estate Equities, Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - Investors who purchased Alexandria Real Estate securities between January 27, 2025, and October 27, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by January 26, 2026 [3] - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [7] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for settlements in 2017 [4] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4] - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, highlighting the firm's expertise and recognition in the field [4] Group 3: Case Background - The lawsuit alleges that defendants provided misleading information regarding Alexandria Real Estate's expected revenue and funds from operations growth for the 2025 fiscal year, particularly concerning its real estate operations [5] - Defendants reportedly made positive statements about leasing activity and occupancy stability while concealing adverse facts about the true state of its Long Island City property [6] - The lawsuit claims that when the true details were revealed, investors suffered damages due to the misleading information provided [6]

Core Viewpoint - A class action lawsuit has been filed against Alexandria Real Estate Equities, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1]. Group 1: Lawsuit Details - The lawsuit is based on claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, representing investors in Alexandria Real Estate securities [3]. - Investors have until January 26, 2026, to request to be appointed to lead the case, which is pending in the U.S. District Court for the Central District of California [3]. Group 2: Company Background - Alexandria Real Estate is a real estate investment trust focused on tenants in life science industries, including pharmaceutical and biotechnology companies [4]. Group 3: Financial Performance and Stock Impact - Alexandria Real Estate reported lower-than-expected results for Q3 2025, leading to a stock price drop of $14.93 per share, or over 19%, from $77.87 to $62.94 on October 27-28, 2025 [6]. - The company announced a real estate impairment charge of $323.9 million, with $206 million attributed to a property in Long Island City, indicating lower occupancy rates and slower leasing activity [5][6].

Core Viewpoint - A class action lawsuit has been filed against Alexandria Real Estate Equities, Inc. for allegedly making materially false and misleading statements regarding the company's Long Island City property and its leasing value as a life-science destination during the Class Period from January 27, 2025, to October 27, 2025 [3][7]. Allegation Details - The lawsuit claims that the defendants provided overwhelmingly positive statements while concealing adverse facts about the true state of the Long Island City property [3]. - It is alleged that the company's claims regarding the leasing value of the LIC property were misleading and lacked a reasonable basis, particularly concerning the Megacampus™ strategy [3]. - As a result, the defendants' statements about the company's business, operations, and prospects were materially false and misleading throughout the relevant period [3]. Next Steps - Investors who purchased Alexandria shares and suffered losses are encouraged to contact the law firm for more information about their rights and potential claims [4][7]. - There is no cost or obligation for investors to inquire about their legal options [4]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in various types of litigation, including securities and commercial litigation [5]. - The firm operates nationwide and handles cases in both federal and state courts [5].

Core Viewpoint - A class action lawsuit has been filed against Alexandria Real Estate Equities, Inc. for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Central District of California, captioned Hern v. Alexandria Real Estate Equities, Inc., et al., No. 2:25-cv-11319 [3]. - Investors have until January 26, 2026, to request to be appointed to lead the case [3]. Group 2: Company Background - Alexandria Real Estate is a real estate investment trust focused on tenants in life science industries, including pharmaceutical and biotechnology companies [4]. Group 3: Financial Performance - Alexandria Real Estate reported lower-than-expected results for Q3 2025, leading to a stock price drop of $14.93 per share, or over 19%, from $77.87 to $62.94 on October 28, 2025 [6]. - The company announced a real estate impairment charge of $323.9 million, with $206 million attributed to its Long Island City property, which was deemed not suitable for life science scaling [5][6].

Core Viewpoint - Alexandria Real Estate Equities, Inc. is facing a securities class action lawsuit due to alleged failure to disclose material information during the class period, which has resulted in significant financial losses for investors [3]. Group 1: Lawsuit Details - Investors who suffered substantial losses from purchasing Alexandria's securities between January 27, 2025, and October 27, 2025, have until January 26, 2026, to file lead plaintiff applications [1]. - The lawsuit is pending in the United States District Court for the Central District of California [1]. - The case is identified as Warren Hern v. Alexandria Real Estate Equities, Inc., et al., No. 25-cv-11319 [5]. Group 2: Financial Performance - On October 27, 2025, Alexandria disclosed third-quarter financial results for fiscal year 2025 that fell below expectations, including a reduction in its Funds From Operations (FFO) guidance for the full year due to lower occupancy rates and slower leasing activity [4]. - The company reported a significant real estate impairment charge of $323.9 million, with $206 million attributed to its LIC property [4]. Group 3: Market Reaction - Following the financial disclosure, Alexandria's share price dropped from $77.87 per share on October 27, 2025, to $62.94 per share on October 28, 2025, marking a decline of approximately 19% in just one day [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Alexandria Real Estate Equities, Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Alexandria Real Estate securities between January 27, 2025, and October 27, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by January 26, 2026 [3] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company and being ranked No. 1 for securities class action settlements in 2017 [4] - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4] Group 3: Case Background - The lawsuit alleges that defendants provided misleading information regarding Alexandria Real Estate's expected revenue and funds from operations (FFO) growth for the 2025 fiscal year, particularly concerning its real estate operations [5] - Defendants reportedly made positive statements about leasing activity and occupancy stability while concealing adverse facts about the true state of its Long Island City property, leading to investor damages when the truth was revealed [6]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Alexandria Real Estate Equities, Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - Investors who purchased Alexandria Real Estate securities between January 27, 2025, and October 27, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by January 26, 2026 [3] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for the number of settlements in 2017 [4] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4] Group 3: Case Background - The lawsuit alleges that defendants provided misleading information regarding Alexandria Real Estate's expected revenue and funds from operations growth for the 2025 fiscal year, particularly concerning its real estate operations [5] - Defendants reportedly made positive statements about leasing activity and occupancy stability while concealing adverse facts about the true state of its Long Island City property, leading to investor damages when the truth emerged [6]

NEW YORK, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Leading international securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Alexandria Real Estate Equities, Inc. (NYSE:ARE) and certain of the Company’s senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws. If you invested in Alexandria Real Estate, you are encouraged to obtain additional information by visiting: https://ww ...

Core Viewpoint - A class action lawsuit has been filed against Alexandria Real Estate Equities, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Central District of California, captioned Hern v. Alexandria Real Estate Equities, Inc., et al., No. 2:25-cv-11319 [3]. - Investors have until January 26, 2026, to request to be appointed to lead the case [3]. Group 2: Company Background - Alexandria Real Estate is a real estate investment trust focused on tenants in life science industries, including pharmaceutical and biotechnology companies [4]. Group 3: Financial Performance and Stock Impact - Alexandria Real Estate reported lower-than-expected results for Q3 2025, leading to a stock price drop of $14.93 per share, or over 19%, from $77.87 to $62.94 on October 27-28, 2025 [6]. - The company announced a real estate impairment charge of $323.9 million, with $206 million attributed to its Long Island City property, which was deemed not suitable for life science scaling [5][6].

Core Thesis - Alexandria Real Estate Equities, Inc. (ARE) has recently faced significant challenges leading to a bearish outlook, primarily due to a 45% dividend cut, which has surprised many investors [2][4]. Company Overview - ARE is a prominent landlord in the life sciences sector, owning large "Mega Campuses" in innovation hubs such as Boston, San Francisco, and San Diego, and leasing to major pharmaceutical companies and biotech firms [2]. Financial Performance - As of January 13th, ARE's share price was $54.64, with trailing and forward P/E ratios of 150.89 and 16.69 respectively [1]. - The company has a strong balance sheet and high-quality assets, but its concentration in life sciences has exposed it to a structural downturn [3]. Industry Challenges - Four major headwinds affecting ARE include tightening NIH funding, declining venture capital for startups, FDA leadership turnover and delayed approvals, and government pricing pressure on drugs, all of which have strained tenant revenue prospects [3]. - There is a dramatic oversupply of lab space, which has increased 7.5 times since 2021, while demand has dropped by 60%, leading to a projected 8.5% reduction in cash flows per building by 2026 and a nearly 30% expected decline in FFO [4]. Dividend and Future Outlook - The necessity of the dividend cut is attributed to the structural pressures that fundamentally reduce future earnings power, despite core tenants remaining operational [4]. - The situation underscores the importance of evaluating industry-specific risks and the relationship between tenant health and landlord performance, even for well-managed REITs [5]. Market Position - ARE is not among the 30 most popular stocks among hedge funds, with 31 hedge fund portfolios holding ARE at the end of the third quarter, down from 33 in the previous quarter [7].